Semaglutide Linked to Rare Hip Bone Weakening in Case Study
Background
Transient osteoporosis of the hip (TOH) is a rare, self-limiting bone marrow edema syndrome characterized by acute hip pain. While metabolic, mechanical, and vascular factors have been proposed as causes, the underlying etiology of TOH remains unclear, and its potential association with semaglutide has not been previously reported.
Results
A healthy middle-aged man experienced sequential unilateral Transient Osteoporosis of the Hip (TOH). The first episode occurred after initiating semaglutide, with symptoms resolving upon drug discontinuation. A second, similar episode of TOH developed upon semaglutide re-exposure, again resolving after the drug was stopped and conservative treatment was applied. > The patient experienced two distinct episodes of Transient Osteoporosis of the Hip (TOH), each occurring after initiation or re-initiation of semaglutide, strongly suggesting a temporal link. This consistent pattern indicates a potential association between semaglutide and the development of TOH, a previously unobserved musculoskeletal complication.
Why It Matters
This case report is highly significant given the rapidly expanding use of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, including its off-label use for weight loss. This finding suggests a potential, previously unrecognized adverse effect of semaglutide on bone health, warranting increased clinical vigilance. Clinicians should now consider Transient Osteoporosis of the Hip (TOH) in the differential diagnosis for patients presenting with acute atraumatic hip pain while on semaglutide. Further large-scale observational studies and mechanistic research are crucial to confirm this association and understand its underlying biological pathways.